Bone Update: Is It Still an Issue Without Tenofovir Disoproxil Fumarate?
Curr HIV/AIDS Rep
; 17(1): 1-5, 2020 Feb.
Article
em En
| MEDLINE
| ID: mdl-31953646
ABSTRACT
PURPOSE OF REVIEW In the era of modern bone-friendly antiretroviral therapy (ART) regimens for people living with HIV (PLWH), this review discusses the research gaps and management concerns that remain for individuals who have already been exposed to ART with negative effects on bone metabolism, especially children and adolescents who have not acquired peak bone mass, and older adults who have additional risk factors for fracture. RECENT FINDINGS:
Data now support the use of avoidance of TDF and use of bone-friendly regimens that include integrase strand transfer inhibitors in PLWH with increased risk of fracture for either ART initiation or switch. Despite significant advances in our understanding of ART choice for PLWH with regard to bone health, additional diagnostic tests to determine fracture risk and management strategies beyond ART choice are necessary, especially in vulnerable PLWH populations, such as children and adolescents and older adults.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Osteoporose
/
Densidade Óssea
/
Fármacos Anti-HIV
/
Tenofovir
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Aged
/
Child
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article